{"id":648537,"date":"2023-04-24T09:16:01","date_gmt":"2023-04-24T09:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=648537"},"modified":"2023-04-24T09:16:01","modified_gmt":"2023-04-24T09:16:01","slug":"whim-syndrome-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-x4-pharmaceuticals-niaid-gsk-plc-bristol-myers-squibb","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/whim-syndrome-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-x4-pharmaceuticals-niaid-gsk-plc-bristol-myers-squibb_648537.html","title":{"rendered":"WHIM Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies &#8211; X4 Pharmaceuticals, NIAID, GSK plc, Bristol Myers Squibb"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1681993257.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"WHIM Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - X4 Pharmaceuticals, NIAID, GSK plc, Bristol Myers Squibb\" src=\"https:\/\/www.abnewswire.com\/uploads\/1681993257.jpeg\" alt=\"WHIM Syndrome Market to Exhibit Moderate Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - X4 Pharmaceuticals, NIAID, GSK plc, Bristol Myers Squibb\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cWHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the WHIM Syndrome.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the WHIM Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the WHIM Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/whim-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">WHIM Syndrome Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the WHIM Syndrome Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The WHIM Syndrome market size was valued approximately <strong>USD 8 Million<\/strong> in 2021 and is anticipated to grow with a significant CAGR during the study period <strong>(2019-2032)<\/strong><\/li>\n<li>In 2021, the total prevalent cases of WHIM Syndrome were the highest in the US, with around<strong> 70 cases<\/strong>, and lowest in Spain with around 10 cases<\/li>\n<li>There were approximately 30 males and 40 females affected by WHIM Syndrome in the United States in 2021, and it is estimated that the prevalence will increase and reach up to 50 males and 75 females by 2032<\/li>\n<li>Among EU5 countries, Germany had the highest number of prevalent cases of WHIM Syndrome (Around 20 cases) in 2021<\/li>\n<li><strong>Key WHIM Syndrome Companies:<\/strong> X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences, and others<\/li>\n<li><strong>Key WHIM Syndrome Therapies:<\/strong> Mavorixafor, Plerixafor, X4P-001, and others<\/li>\n<li>The WHIM Syndrome epidemiology based on gender analyzed that males and females contributed approximately 30 and 45 WHIM Syndrome cases in 2021 in EU-5<\/li>\n<li>The WHIM Syndrome market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage WHIM Syndrome pipeline products will significantly revolutionize the WHIM Syndrome market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is an ultra-rare and difficult-to-diagnose primary immunodeficiency disease. In almost all patients of WHIM syndrome, the disease is caused by &ldquo;gain-of-function&rdquo; mutations in the single gene that encodes for the CXCR4 receptor.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the WHIM Syndrome Market Report &#8211;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/whim-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/whim-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The WHIM Syndrome market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of WHIM Syndrome<\/li>\n<li>Prevalent Cases of WHIM Syndrome by severity<\/li>\n<li>Gender-specific Prevalence of WHIM Syndrome<\/li>\n<li>Diagnosed Cases of Episodic and Chronic WHIM Syndrome<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving WHIM Syndrome epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/whim-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">WHIM Syndrome Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the WHIM Syndrome market or expected to get launched during the study period. The analysis covers WHIM Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the WHIM Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Mavorixafor:<\/strong> X4 Pharmaceuticals<\/li>\n<li><strong>Plerixafor:<\/strong> NIAID<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major WHIM Syndrome market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/whim-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">WHIM Syndrome Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Emerging drugs like mavorixafor in late-stage clinical development with strong clinical data for treating neutropenia, lymphopenia, sustained improvements in infections and warts in WHIM syndrome patients<\/li>\n<li>Support from regulatory authorities by granting ODD status, Breakthrough Designations, and rare pediatric disease designations to encourage clinical drug development for the treatment of ultra-rare diseases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>WHIM Syndrome Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>There are no disease-specific approved therapies for the treatment of WHIM syndrome<\/li>\n<li>The first product approved for the treatment of WHIM is likely to get a first-mover advantage across the 7MM<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the WHIM Syndrome Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key WHIM Syndrome Companies:<\/strong> X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., Horizon Therapeutics plc, Amgen, and Leadiant Biosciences, and others<\/li>\n<li><strong>Key WHIM Syndrome Therapies:<\/strong> Mavorixafor, Plerixafor, X4P-001, and others<\/li>\n<li><strong>WHIM Syndrome Therapeutic Assessment:<\/strong> WHIM Syndrome current marketed and WHIM Syndrome emerging therapies<\/li>\n<li><strong>WHIM Syndrome Market Dynamics:<\/strong> WHIM Syndrome market drivers and WHIM Syndrome market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>WHIM Syndrome Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, WHIM Syndrome Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about WHIM Syndrome companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/whim-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">WHIM Syndrome Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. WHIM Syndrome Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for WHIM Syndrome<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of WHIM Syndrome<\/p>\n<p style=\"text-align: justify;\">4. WHIM Syndrome Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. WHIM Syndrome Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. WHIM Syndrome Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. WHIM Syndrome Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of WHIM Syndrome&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. WHIM Syndrome Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. WHIM Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. WHIM Syndrome Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. WHIM Syndrome Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise WHIM Syndrome Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. WHIM Syndrome Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. WHIM Syndrome Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. WHIM Syndrome Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; WHIM Syndrome Appendix<\/p>\n<p style=\"text-align: justify;\">18. WHIM Syndrome Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=whim-syndrome-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-x4-pharmaceuticals-niaid-gsk-plc-bristol-myers-squibb\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=whim-syndrome-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-x4-pharmaceuticals-niaid-gsk-plc-bristol-myers-squibb\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cWHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the WHIM Syndrome. DelveInsight&rsquo;s &ldquo;WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/whim-syndrome-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-20222032-investigates-delveinsight-key-companies-x4-pharmaceuticals-niaid-gsk-plc-bristol-myers-squibb_648537.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-648537","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/648537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=648537"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/648537\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=648537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=648537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=648537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}